ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 40977663

Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma.

Zhan TA and 5 others. World J Gastrointest Oncol, 2025. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma. Papers, record 40977663. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40977663

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma.
PubMed
Journal
World J Gastrointest Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-09-24
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhan TATian-Ao
2Xia FFeng
3Huang HWHong-Wei
4Zhan JCJun-Cheng
5Liu XKXin-Kang
6Cheng QQi

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References130

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129,733,511Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.Cancer Med2018https://conductscience.org/library/papers/29733511PubMed
234,199,304FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice.Cancers (Basel)2021https://conductscience.org/library/papers/34199304PubMed
317,255,361Inhibitory effect of tumor cell-derived lactic acid on human T cells.Blood2007https://conductscience.org/library/papers/17255361PubMed
437,976,704Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges.Eur J Med Chem2024https://conductscience.org/library/papers/37976704PubMed
527,192,118Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.Oncotarget2016https://conductscience.org/library/papers/27192118PubMed
635,844,605Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.Front Immunol2022https://conductscience.org/library/papers/35844605PubMed
722,224,781Regulatory T cells: mechanisms of differentiation and function.Annu Rev Immunol2012https://conductscience.org/library/papers/22224781PubMed
820,018,895FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.J Biol Chem2010https://conductscience.org/library/papers/20018895PubMed
933,249,195Small hepatitis B virus surface antigen promotes malignant progression of hepatocellular carcinoma via endoplasmic reticulum stress-induced FGF19/JAK2/STAT3 signaling.Cancer Lett2021https://conductscience.org/library/papers/33249195PubMed
1032,154,250Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.Front Cell Dev Biol2020https://conductscience.org/library/papers/32154250PubMed

1 to 10 of 130

See all 130 references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42,824,816FGFR signaling and apoptotic regulation in cancer: links to immune evasion, therapeutic resistance, and treatment re-engagement.Front Immunol2026https://conductscience.org/library/papers/42824816

Source PubMed

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FGF199,965PubTator's text mininghttps://conductscience.org/library/genes/9965NCBI Gene
FGFR42,264PubTator's text mininghttps://conductscience.org/library/genes/2264NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40977663

GET https://conductscience.org/api/papers/v1/40977663/references?page=2

API referenceFor AI assistants